Thu, July 7, 2022
Wed, July 6, 2022
Tue, July 5, 2022
Mon, July 4, 2022
Sun, July 3, 2022
Fri, July 1, 2022
Thu, June 30, 2022
Wed, June 29, 2022

Andrew Berens Maintained (BPMC) at Hold with Decreased Target to $56 on, Jul 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-56-on-jul-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Andrew Berens of SVB Leerink, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $60 to $56 on, Jul 1st, 2022.

Andrew has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022


These are the ratings of the 4 analyists that currently disagree with Andrew


  • Derek Archila of "Wells Fargo" Initiated at Sell and Held Target at $40 on, Monday, June 27th, 2022
  • David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022

Publication Contributing Sources